IPO Update: Novan, AC Immune End Summer Slowdown As Market Improves
Novan and AC Immune ended September with the first biopharma IPOs in 40 days as the performance of newly public companies’ stocks head into an upswing.
You may also be interested in...
Nitric oxide-releasing SB206 missed the primary endpoint in a pair of Phase III studies, but Novan hopes a third study and success on a secondary endpoint still can lead to filing for approval.
Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.
The Swiss biotech, AC Immune, has identified further antibodies aimed at targets in neurodegenerative diseases that could complement its work in beta-amyloid and tau-based approaches to conditions like Alzheimer's disease.